COMP <GO>
CDNA vs ABBV // REVENUE GROWTH (YOY)
CareDx Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: CDNA 5
— ABBV 8
▲ REVENUE GROWTH (YOY) LEADER: CDNA
LAST: $87.41 (+22.22%) • MKT CAP: $3.70B
revenue-growth
13.80%
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
revenue-growth
8.60%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CDNA VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CDNA | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 70.20% | -29.20 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -8.20% | 29.00% | -37.20 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 0.67% | 3.47% | -2.80 | ABBV | /fcf-yield <GO> |
| Operating Margin | -8.10% | 24.60% | -32.70 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -5.60% | 6.90% | -12.50 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 13.80% | 8.60% | +5.20 | CDNA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 19.22 | 5.33 | +13.89 | CDNA | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.10% | 7.40% | -0.30 | CDNA | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 81.9 | 72.8 | +9.12 | CDNA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.06 | 1.15 | -0.09 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 21.0x | 113.1x | -92.10 | CDNA | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.70B | $513.86B | -$510.16B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CDNA REV | ABBV REV | CDNA GROSS % | ABBV GROSS % | CDNA FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $379.8M | $61.16B | 44.0% | 70.2% | $24.9M | $17.82B |
| FY 2024 | $333.8M | $56.33B | 44.0% | 70.0% | $23.0M | $17.83B |
| FY 2023 | $280.3M | $54.32B | 44.0% | 44.0% | -$31.0M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CDNA // BETA 1.06
ABBV // BETA 1.15